FDA Recommends Study Designs for BE Studies With Pharmacokinetic Endpoints

Drug Industry Daily
A A
In an effort to head off one of the most common problems that sidetracks ANDA submissions, the FDA is telling drugmakers that bioequivalence studies for most drugs submitted as ANDAs should use a two-period, two-sequence, single-dose, crossover study design.

To View This Article:

Login

Subscribe To Drug Industry Daily